5207 related articles for article (PubMed ID: 3844970)
1. Antitumor properties of vindesine-monoclonal antibody conjugates.
Rowland GF; Axton CA; Baldwin RW; Brown JP; Corvalan JR; Embleton MJ; Gore VA; Hellström I; Hellström KE; Jacobs E
Cancer Immunol Immunother; 1985; 19(1):1-7. PubMed ID: 3844970
[TBL] [Abstract][Full Text] [Related]
2. Experience in the preparation and experimental use of immunocytostatics.
Embleton MJ; Pimm MV; Garnett MC; Rowland GF; Simmonds RG; Baldwin RW
Behring Inst Mitt; 1984 May; (74):108-12. PubMed ID: 6591915
[TBL] [Abstract][Full Text] [Related]
3. Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft.
Rowland GF; Simmonds RG; Gore VA; Marsden CH; Smith W
Cancer Immunol Immunother; 1986; 21(3):183-7. PubMed ID: 2421898
[TBL] [Abstract][Full Text] [Related]
4. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
Embleton MJ; Rowland GF; Simmonds RG; Jacobs E; Marsden CH; Baldwin RW
Br J Cancer; 1983 Jan; 47(1):43-9. PubMed ID: 6571783
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
Conrad RA; Cullinan GJ; Gerzon K; Poore GA
J Med Chem; 1979 Apr; 22(4):391-400. PubMed ID: 430477
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and selectivity of vindesine monoclonal anti-carcinoembryonic antigen antibody conjugates on human tumor cell lines grown as xenografts in nude mice.
Casson AG; Ford CH; Marsden CH; Gallant ME; Bartlett SE
NCI Monogr; 1987; (3):117-24. PubMed ID: 3821911
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies for radioimmunodetection of tumours and for targeting.
Baldwin RW; Embleton MJ; Pimm MV
Bull Cancer; 1983; 70(2):132-6. PubMed ID: 6575842
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and specificity of vindesine monoclonal anti-carcinoembryonic antigen conjugate with nine human cancer cell lines.
Ford CH; Bartlett SE; Casson AG; Marsden CH; Gallant ME
NCI Monogr; 1987; (3):107-16. PubMed ID: 3547144
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen.
Starling JJ; Maciak RS; Hinson NA; Nichols CL; Briggs SL; Laguzza BC; Smith W; Corvalan JR
Bioconjug Chem; 1992; 3(4):315-22. PubMed ID: 1382618
[TBL] [Abstract][Full Text] [Related]
10. Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
Ford CH; Newman CE; Johnson JR; Woodhouse CS; Reeder TA; Rowland GF; Simmonds RG
Br J Cancer; 1983 Jan; 47(1):35-42. PubMed ID: 6821632
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog].
Ashizawa T; Miyoshi K; Asada M; Kobayashi E; Okabe M; Morimoto M; Gomi K; Hirata T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):59-66. PubMed ID: 8422187
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
[TBL] [Abstract][Full Text] [Related]
13. New application of human tumor clonogenic assay to in vitro evaluation of tumor-targeting efficiency of immunoconjugates.
Nagata S; Masuda K; Nogusa H; Hirano K; Takagishi Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2151-4. PubMed ID: 1423771
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.
Starling JJ; Maciak RS; Hinson NA; Nichols CL; Briggs SL; Laguzza BC
Cancer Immunol Immunother; 1989; 28(3):171-8. PubMed ID: 2784353
[TBL] [Abstract][Full Text] [Related]
15. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting.
Baldwin RW; Pimm MV
Cancer Metastasis Rev; 1983; 2(1):89-106. PubMed ID: 6352009
[TBL] [Abstract][Full Text] [Related]
16. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of murine CFU-C by vindesine: restoration of colony growth by colony stimulating factor.
Pigoli G; Mangoni L; Caramatti C; Degliantoni G; Rizzoli V
Int J Cell Cloning; 1983 Jul; 1(3):142-50. PubMed ID: 6609213
[TBL] [Abstract][Full Text] [Related]
18. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
[TBL] [Abstract][Full Text] [Related]
19. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
